Document:

ptx_ex102.htm

    EXHIBIT
10.2

    
 

    

     

    Zyber
– Macoven Pharmaceuticals Agreement

     

    

    
      	
               
      

            	
              Introduction:

            

    

    

    An
agreement (“AGREEMENT”) is made this 27th day of July, 2009 by and between Zyber
Pharmaceuticals, Inc. (“Zyber”),  a Louisiana Corporation having an
office at 208 East Bank Drive, Gonzales, Louisiana 70737 and Macoven
Pharmaceuticals, LLC. (“Macoven Pharmaceuticals”), a Louisiana Limited Liability
Company.  Zyber and Macoven Pharmaceuticals may be collectively
referred to as the “Parties.”

    

    RECITALS:

    

    WHEREAS,
Zyber currently promotes various pharmaceutical products;

    

    WHEREAS,
Macoven Pharmaceuticals also currently promotes various pharmaceutical
products;

    

    WHEREAS,
Zyber desires to into an agreement with Macoven Pharmaceuticals for Macoven
Pharmaceuticals to have the right to develop and sell generic pharmaceutical
products based on and/or derived from Zyber’s pharmaceutical products whereby
Zyber will pay Macoven Pharmaceuticals a one time development fee and all sales
proceeds from Macoven Pharmaceuticals’ sales of said generic pharmaceutical
products will belong to and be paid to Zyber; and

    

    WHEREAS,
Macoven Pharmaceuticals wishes to enter into an agreement with Zyber so that
Macoven Pharmaceuticals can develop and sell generic pharmaceutical products
based on Zyber’s pharmaceutical products whereby Macoven Pharmaceuticals will
pay Zyber an administrative fee for administrative services that Zyber performs
for Macoven Pharmaceuticals.

    

    NOW
THEREFORE, in consideration of the promises and of the mutual covenants and
agreements herein contained, receipts and sufficiency of which is hereby
acknowledged, the Parties hereby agree as follows:

    

    
      	
              1.

            	
              DEFINITIONS

            

    

    

    
      	
               
      

            	
              1.1.

            	
              “ACTION
      OR PROCEEDING” means any action, suit, proceeding, arbitration, Order,
      inquiry, hearing, assessment with respect to fines or penalties, or
      litigation (whether civil, criminal, administrative, investigative or
      informal) commenced, brought, conducted or heard by or before, or
      otherwise involving, any Governmental or Regulatory
    Authority.

            

    

    

    
      	
               
      

            	
              1.2.

            	
              “APPLICABLE
      LAWS” means all applicable statutes, ordinances, regulations, rules or
      orders of any kind whatsoever of any government authority or court of
      competent jurisdiction, including, without limitation, the Federal Food,
      Drug, and Cosmetic Act (21 U.S.C. §301 et
seq.),

            

    

    
      
         

          
             

          

        

      

      
        Page 1 of
11

        
          

        

      

      
         

        
          
             

          

        

      

    

    

    
      	
               
      

            	
              1.3.

            	
              “PRODUCTS
      ” means any past, current, and/or future Zyber pharmaceutical product
      including, generics for Zyber brand products.

            

    

    

    
      	
               
      

            	
              1.4.

            	
              “THIRD
      PARTY” means any business entities or individuals other than Zyber or
      Macoven Pharmaceuticals.

            

    

    

    
      	
               
      

            	
              1.5.

            	
              “ADMINISTRATIVE
      SERVICES” means any acts/services performed by Zyber, its subsidiaries,
      affiliates, or its successor(s) in interest or any acts/services performed
      on behalf of Zyber that are performed for the benefit of Macoven
      Pharmaceuticals or any of its subsidiaries, affiliates, parents, and/or
      successor(s) in interest, regarding the administration, distribution,
      and/or management of distribution of any products sold by Macoven
      Pharmaceuticals under the terms of this
  AGREEMENT.

            

    

    

    
      	
               
      

            	
              1.6.

            	
              “KNOW-HOW”
      means all product specifications; manufacturing, physical chemistry and
      formulation know-how; analytical testing methods and validations;
      technical knowledge; expertise; skill; practices and procedures; formulae;
      trade secrets; confidential information; analytical methodology;
      processes; preclinical, clinical, stability and other data and results;
      market studies; and all other experience and know-how, in each case in
      tangible form and only to the extent related to Zyber and the PRODUCTS,
      whether or not patentable, together with inventions and methods (whether
      patentable or unpatentable and whether or not reduced to practice) and all
      improvements to those inventions and
methods.

            

    

    

    
      	
              2.

            	
              TERMS

            

    

    

    
      	
               
      

            	
              2.1.

            	
              Ownership:  Subject
      to the other terms and conditions of this AGREEMENT, Zyber and Macoven
      Pharmaceuticals acknowledge, agree, and understand that Zyber currently
      owns and will retain ownership in all rights of any kind, including but
      not limited to intellectual property rights, trademarks, copyrights,
      patents, KNOW-HOW, trade secrets, and the like in all of Zyber’s current,
      past, and future PRODUCTS.  This AGREEMENT does not assign,
      transfer, convey, or change those ownership rights in any
    way.

            

    

    

    
      	
               
      

            	
              2.2.

            	
              License:  Macoven
      Pharmaceuticals acknowledges, agrees, and understands that this AGREEMENT
      acts as a non-exclusive license agreement whereby for a one-time fee,
      discussed herein pursuant to Section 6, and for a set term, as discussed
      herein pursuant to Section 5, Macoven Pharmaceuticals is given the
      non-exclusive right to develop, market, and sell generic pharmaceutical
      products based on and/or derived from Zyber’s
  PRODUCTS.

            

    

    

    
      	
               
      

            	
              2.3.

            	
              Marketing:  Subject
      to the other terms and conditions of this AGREEMENT, Zyber and Macoven
      Pharmaceuticals acknowledge, agree, and understand that Zyber, its
      partners, affiliates, its subsidiaries, and/or its successors in
      interests, shall have the right to use any marketing materials developed
      by and/or for Macoven Pharmaceuticals for marketing and/or selling any
      products developed as a result of this
  AGREEMENT.

            

    

    

    

    
      
        
           

        

         

      

      
        Page 2 of
11

        
          

        

      

      
         

        
           

        

      

    

    2.4.           Exclusiveness:  Zyber
and Macoven Pharmaceuticals acknowledge, agree, and understand that the rights
granted to Macoven Pharmaceuticals under this AGREEMENT are non-exclusive and
Zyber has the right to grant the same and/or similar rights to any THIRD PARTY
at Zyber’s discretion.

    

    
      	
               
      

            	
              2.5.

            	
              Distribution:  Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that
      Macoven Pharmaceuticals is responsible for the distribution and marketing
      of any products developed as a result of this
      AGREEMENT.  However, Zyber and Macoven Pharmaceuticals further
      acknowledge, agree, and understand that Macoven Pharmaceuticals can choose
      to pay Zyber an agreed upon fee, as discussed herein pursuant to Section
      8, for Zyber to assist Macoven Pharmaceuticals by providing Administrative
      Services, distribution, marketing, and/or other services for the benefit
      of Macoven Pharmaceuticals.

            

    

    

    
      	
              3.

            	
              PRODUCT
      COMMERCIALIZATION

            

    

    

    
      	
               
      

            	
              3.1.

            	
              Subject
      to the other terms and conditions of this AGREEMENT, Zyber and Macoven
      Pharmaceuticals acknowledge, agree, and understand that Zyber retains
      complete control over the commercialization and promotion of any and all
      products developed, marketed, and sold as a result of this
      AGREEMENT.

            

    

    

    
      	
               
      

            	
              3.2.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that
      Macoven Pharmaceuticals will consult with Zyber and obtain Zyber’s consent
      prior to partaking in any activity that would be considered the
      commercialization and/or promotion of any products developed as a result
      of this AGREEMENT.

            

    

    

    
      	
              4.

            	
              MANUFACTURE
      OF PRODUCTS

            

    

    

    
      	
               
      

            	
              4.1.

            	
              Any
      products developed as a result of this AGREEMENT will be manufactured at a
      location that is acceptable to
Zyber.

            

    

    

    
      	
               
      

            	
              4.2.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that Zyber
      has the right and control to make all final approvals and/or other
      decisions regarding the manufacturing of any products developed as a
      result of this AGREEMENT.

            

    

    

    
      	
               
      

            	
              4.3.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that
      Macoven Pharmaceuticals is solely responsible for any and all payments to
      any manufacturer for the development and/or manufacturing of any products
      developed as a result of this
AGREEMENT.

            

    

    

    
      	
              5.

            	
              TERM

            

    

    

    
      	
               
      

            	
              5.1.

            	
              The
      initial term (“INITIAL TERM”) of this AGREEMENT is eighteen (18)
      months.

            

    

    

    

    

    

    
      
        
           

        

         

      

      
        Page 3 of
11

        
          

        

      

      
         

        
           

        

      

    

    5.2.                 After
expiration of the INITIAL TERM described in 5.1, this AGREEMENT shall
automatically renew for 12 months unless Zyber chooses not to
renew.  This AGREEMENT will then renew for a new 12 month term at the
end of each 12 month period unless otherwise terminated by Zyber as provided for
under the terms of this AGREEMENT.

    

    
      	
               
      

            	
              5.3.

            	
              The
      overall term of this AGREEMENT shall commence on the __________ day of
      _____________, 2009, and expire after the INITIAL TERM, unless this
      AGREEMENT is terminated sooner by Zyber or unless this AGREEMENT is
      renewed pursuant to the terms and conditions
  hereof.

            

    

    

    
      	
               
      

            	
              5.4.

            	
              Zyber
      has the right to terminate this AGREEMENT after the INITIAL TERM at
      will.  Macoven Pharmaceuticals can only terminate this AGREEMENT
      with 90 days notice.

            

    

    

    
      	
               
      

            	
              5.5.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that Zyber
      must provide 30 days advance notice to Macoven Pharmaceuticals before
      terminating this AGREEMENT.

            

    

    

    
      	
               
      

            	
              5.6.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that if
      both Zyber and Macoven Pharmaceuticals agree to terminate this AGREEMENT,
      then this AGREEMENT may be terminated at
  anytime.

            

    

    

    
      	
              6.

            	
              PAYMENTS
      BY ZYBER TO MACOVEN PHARMACEUTICALS

            

    

    

    
      	
               
      

            	
              6.1.

            	
              Zyber
      agrees to pay to Macoven Pharmaceuticals a one time development and
      service fee (“DEVELOPMENT FEE”) of One Million Five Hundred Thousand and
      00/100 ($1,500,000.00) for developing, promoting, commercializing,
      marketing, and selling any pharmaceutical products that are based on
      and/or derived from Zyber’s PRODUCTS.  This development and
      service fee will be paid in full or partial payments within 10 days of a
      request in writing by Macoven Pharmaceuticals.  Zyber can deduct
      this payment from credit that Zyber has with
  Macoven.

            

    

    

    
      	
               
      

            	
              6.2.

            	
              Upon
      execution of this AGREEMENT by the Parties, Zyber agrees to pay Macoven
      Pharmaceuticals Twenty Thousand and 00/100 ($20,000.00) dollars
      representing payment of a portion of the DEVELOPMENT FEE set forth in
      section 6.1 of this AGREEMENT.  If for any reason, this
      AGREEMENT terminates during the first SIX (6) months, then Macoven
      Pharmaceuticals acknowledges, agrees, and understands that Zyber is only
      required to pay Macoven Pharmaceuticals one-third (1/3) or thirty-three
      percent (33%)  of the DEVELOPMENT
FEE.

            

    

    

    
      	
               
      

            	
              6.3.

            	
              Zyber
      agrees to pay Macoven Pharmaceuticals the full DEVELOPMENT FEE by the end
      of the INITIAL TERM, unless the AGREEMENT is terminated prior to the
      expiration of the INITIAL TERM.  In the event that this
      AGREEMENT is terminated prior to the INITIAL TERM, payment will be
      governed by Section 6.4 of this
AGREEMENT.

            

    

    

    
      	
               
      

            	
              6.4.

            	
              In
      the event of a termination of this AGREEMENT prior to the INITIAL TERM,
      Zyber will be responsible for paying Macoven Pharmaceuticals a percentage
      of the DEVELOPMENT FEE

            

    

    
      
        
           

        

         

      

      
        Page 4 of
11

        
          

        

      

      
         

        
           

        

      

    

    
      	
               
      

            	
              based
      upon the number of months that this AGREEMENT has been in effect (“PARTIAL
      DEVELOPMENT FEE”).

            

    

    

    
      	
              7.

            	
              PAYMENTS
      BY MACOVEN PHARMACEUTICALS TO ZYBER/ OWNERSHIP OF
  SALES

            

    

    

    
      	
               
      

            	
              7.1.

            	
              Macoven
      Pharmaceuticals acknowledges, agrees, and understands that all proceeds up
      to 1.5 million dollars during the initial term will be the sole and
      exclusive property of Zyber.

            

    

    

    
      	
               
      

            	
              7.2.

            	
              Macoven
      Pharmaceuticals acknowledges, agrees, and understands that any and all
      payments submitted to Macoven Pharmaceuticals and/or any of its
      affiliates, employees, officers, directors, agents, subsidiaries, or
      successors, from any THIRD PARTIES for any orders of any products
      developed as a result of this AGREEMENT and placed after the execution of
      this AGREEMENT are the exclusive property of
  Zyber.

            

    

    

    
      	
               
      

            	
              7.3.

            	
              Macoven
      Pharmaceuticals acknowledges, agrees, and understands that at the time of
      termination of this AGREEMENT for any reason, any outstanding invoices and
      accounts receivables relating to the sale of any products developed as a
      result of this AGREEMENT will be the exclusive property of and belong to
      Zyber.  Macoven Pharmaceuticals hereby assigns to Zyber full
      ownership of any accounts receivables and outstanding invoices relating to
      sales of any products developed as a result of this
    AGREEMENT.

            

    

    

    
      	
               
      

            	
              7.4.

            	
              Macoven
      Pharmaceuticals acknowledges, agrees, and understands that it is
      responsible for any and all costs and fees, including but not limited to
      attorney’s fees, incurred and/or associated with collecting any sales
      proceeds associated with the sale of any products developed as a result of
      this AGREEMENT.  Macoven Pharmaceuticals acknowledges and agrees
      that it will reimburse Zyber for any costs and/or fees, including but not
      limited to attorney’s fees, incurred and/or expended by Zyber in
      collecting sales proceeds associated with the sale of any products
      developed as a result of this
AGREEMENT.

            

    

    

    
      	
               
      

            	
              7.5.

            	
              Macoven
      Pharmaceuticals agrees to forward all payments due Zyber pursuant to the
      terms of Sections 7.1 to 7.4 to Zyber on at least the 15th
      and 30th
      of each month

            

    

    

    
      	
              8.

            	
              PAYMENT
      FOR ZYBER’S ADMINISTRATIVE SERVICES

            

    

    

    
      	
               
      

            	
              8.1.

            	
              Zyber
      and Macoven Pharmaceuticals acknowledge, agree, and understand that
      Macoven Pharmaceuticals will pay Zyber ten percent (10%) of net profit for
      Zyber providing ADMINISTRATIVE SERVICES and managing all of Macoven
      Pharmaceuticals generic products.

            

    

    

    
      	
              9.

            	
              MISCELLANEOUS

            

    

    

    
      	
               
      

            	
              9.1.

            	
              The
      scope of this AGREEMENT shall include all pages of this AGREEMENT along
      with any and all attachments and/or
exhibits.

            

    

    
      	
               
      

            	
              9.2.

            	
              All
      notices to be given under this AGREEMENT shall be in writing and shall be
      deemed to be fully given by a party when sent by certified or registered
      mail, postage prepaid, or by
reputable

            

    

    
      
        
           

        

         

      

      
        Page 5 of
11

        
          

        

      

      
         

        
           

        

      

    

    
      	
               
      

            	
              overnight
      carrier to the other party at the respective address shown below or to
      such other address as a party hereto shall supply to the other in
      writing:

            

    

    

    

    
      	
              If to Zyber:

              Zyber
      Pharmaceuticals, Inc.

              208
      East Bank Drive

              Gonzales,
      Louisiana 70737

              Attention:
      Cooper Collins

               

            	
              If to Macoven Pharmaceuticals
      :

              Macoven
      Pharmaceuticals, LLC .

               

              COOPER
      NEED ADDRESS

               

              Attention:  Mike
      Venters

            

    

    

    

    
      	
               
      

            	
              9.3.

            	
              All
      terms and provisions of this AGREEMENT shall survive any change of control
      for both Zyber and Macoven Pharmaceuticals.  In addition all
      terms and provisions of this AGREEMENT shall apply to any change of
      ownership for both Zyber and Macoven
  Pharmaceuticals.

            

    

    

    
      	
               
      

            	
              9.4.

            	
              This
      AGREEMENT may be executed in any number of counterparts and by facsimile,
      each of which will be deemed an original, but all of which together will
      constitute one and the same
instrument.

            

    

    
      
        
           

        

         

      

      
        Page 6 of
11

        
          

        

      

      
         

        
           

        

      

    

    

    
      	
              10.

            	
              CONFIDENTIALITY

            

    

    

    
      	
               
      

            	
              10.1.

            	
              Confidential
      Information.  Each party acknowledges and agrees that it will
      have access to, or become acquainted with, Confidential Information of the
      other party in connection with the performance of the services required by
      this AGREEMENT.  For the purposes of this AGREEMENT,
      “Confidential Information” shall mean any information of the disclosing
      party or any affiliate thereof, which gives the disclosing party an
      advantage over its competitors who do not possess such information and
      constitutes valuable trade secrets and proprietary data which was revealed
      to the receiving party as a result of entering into or performing its
      obligations under this AGREEMENT, including but not limited to,
      information which relates to the PRODUCTS, designs, methods, discoveries,
      improvements, documents, trade secrets, proprietary rights, business
      affairs, customer information or employee
      information.  Confidential Information shall not include any
      information that:

            

    

    

    
      	
              10.1.1.

            	
              was
      known to the receiving party prior to the date of this AGREEMENT, without
      an obligation to keep it
confidential;

            

    

    

    
      	
              10.1.2.

            	
              was
      lawfully obtained by the receiving party from a third party without any
      obligation of confidentiality;

            

    

    

    
      	
              10.1.3.

            	
              is,
      at the time of disclosure, in the public
  knowledge;

            

    

    

    
      	
              10.1.4.

            	
              becomes
      part of the public knowledge after disclosure by publication or otherwise
      except by breach of this AGREEMENT;

            

    

    

    
      	
              10.1.5.

            	
              is
      developed by the receiving party independently by persons who did not have
      access to the Confidential information and apart from this
      AGREEMENT.

            

    

    

    
      	
              10.1.6.

            	
              is
      otherwise knowledge possessed by the receiving party or its employees as
      the result of their industry experience or
  education.

            

    

    

    
      	
               
      

            	
              10.2.

            	
              The
      receiving party shall keep all Confidential Information in confidence and
      shall not, at any time during or for a period of five (5) years from the
      termination of this AGREEMENT, without the disclosing party’s prior
      written consent, disclose or otherwise make available, directly or
      indirectly, any item of Confidential Information to anyone other than its
      employees (and its legal counsel and consultants provided they are bound
      by similar obligations of confidentiality) who need to know the same in
      connection with fulfilling the purposes of this AGREEMENT.  The
      receiving party shall use the Confidential Information only in connection
      with fulfilling the purposes of this AGREEMENT and for no other
      purpose.  Each party shall inform its employees of the trade
      secret, proprietary and confidential nature of the Confidential
      Information.

            

    

    

    

    

    
      
        
           

        

         

      

      
        Page 7 of
11

        
          

        

      

      
         

        
           

        

      

    

    

    
      	
               
      

            	
              10.3.

            	
              Extraordinary
      Relief.  Any violation by either Zyber or Macoven
      Pharmaceuticals of its obligations pursuant to the confidentiality
      provisions herein shall not be adequately compensable by monetary damages
      and the non-violating party shall be entitled to an injunction order or
      other appropriate decree specifically enforcing such party’s obligations
      pursuant to the confidentiality provisions of this
      AGREEMENT.  The rights granted by this Section 10.3 are in
      addition to all other remedies and rights available at law or in
      equity.

            

    

    

    
      	
               
      

            	
              10.4.

            	
              Upon
      termination of this AGREEMENT, each party will return the other party’s
      Confidential Information which is under its control or in its
      possession.

            

    

    

    
      	
              11.

            	
              ENFORCEMENT,
      RENEWAL, TERMINATION, AND/OR
GENERAL

            

    

    

    
      	
               
      

            	
              11.1.

            	
              This
      AGREEMENT shall be governed by, and interpreted under, the laws of the
      State of Louisiana without giving effect to the conflicts of laws
      principles.  In the event of a dispute(s), claim(s) or matter(s)
      in question of any kind whatsoever arising out of or related or collateral
      to the provisions and/or subject matter of this AGREEMENT or the breach
      thereof, it is agreed that the parties to this AGREEMENT will attempt to
      resolve such dispute(s), claim(s) or other matter(s) in question amicably
      by informal discussions and negotiations within a seven (7) day
      period.  All dispute(s), claim(s) or other matter(s) in question
      that can not be settled by negotiations among the parties within such time
      shall upon demand of, and at the election of Zyber be submitted by the
      parties to arbitration to take place in the state of
      Louisiana.

            

    

    

    
      	
               
      

            	
              11.2.

            	
              In
      the event that arbitration is not elected by Zyber, then any dispute(s),
      claim(s), controversy, or other matter(s), shall be resolved without a
      jury in a court located in the State of Louisiana.  The parties
      consent to jurisdiction in such courts, waive any objection to such venue
      and waive trial by jury.  The parties stipulate and agree that
      any judgment relating to this AGREEMENT which is entered in a court in the
      State of Louisiana shall be binding throughout the world.  Legal
      Process may be served on either party by Certified Mail, Return Receipt
      Requested or any other method permitted by the rules of the Court in which
      an action is commenced.

            

    

    

    
      	
               
      

            	
              11.3.

            	
              In
      the event that this matter proceeds to arbitration or litigation, the
      prevailing party shall be entitled to collect reasonable attorney’s fees
      for the arbitration and/or
litigation.

            

    

    

    
      	
               
      

            	
              11.4.

            	
              In
      the event that any provision of this AGREEMENT shall be held invalid or
      unenforceable, it shall be deemed modified, but only to the extent
      necessary to make it lawful.  To effect such modification, the
      said provision shall be deemed deleted, added to and/or rewritten,
      whichever shall most fully preserve the intentions of the parties as
      originally expressed herein.

            

    

    

    
      	
               
      

            	
              11.5.

            	
              The
      obligations of the parties under this AGREEMENT shall be binding upon
      their legal assigns and successors, but this AGREEMENT may not be assigned
      by a party to this AGREEMENT to a THIRD PARTY except with the prior
      written consent of the other party.

            

    

    

    

    
      
        
           

        

         

      

      
        Page 8 of
11

        
          

        

      

      
         

        
           

        

      

    

    11.6.              Either
party shall have the right, but not the obligation, to terminate this AGREEMENT
upon (thirty) 30 days written notice after the occurrence of a material breach
of this AGREEMENT.  Such termination shall be without prejudice to any
other right or remedy of the Parties, including, but not limited to, the right
to damages and/or equitable relief and/or to remedy any material breach of this
AGREEMENT.

    

    
      	
              12.

            	
              REPRESENTATIONS
      AND WARRANTIES

            

    

    

    
      	
               
      

            	
              12.1.

            	
              Macoven
      Pharmaceuticals and Zyber represent and warrant that they have the right
      and authority to enter into this AGREEMENT with one
    another.

            

    

    

    
      	
               
      

            	
              12.2.

            	
              This
      AGREEMENT (and any Exhibits attached hereto) supersedes all prior
      discussions and agreements, both written and oral, among the Parties with
      respect to the subject matter hereof and contain the sole and entire
      agreement among the Parties with respect to the subject matter
      hereof.

            

    

    

    
      	
               
      

            	
              12.3.

            	
              Macoven
      Pharmaceuticals represents and warrants that there are no Actions or
      Proceedings pending, threatened or reasonably anticipated against Macoven
      Pharmaceuticals or its Affiliates that relate to (a) pharmaceutical
      products currently or previously sold by Macoven Pharmaceuticals; (b) this
      Agreement; or (c) the transactions contemplated by this
      Agreement.  Macoven Pharmaceuticals is not subject to any Order
      that could reasonably be expected to materially impair or delay the
      ability of Macoven Pharmaceuticals to perform its obligations
      hereunder.

            

    

    

    
      	
               
      

            	
              12.4.

            	
              Paragraph/Section
      headings herein are for convenience only and do not control or affect the
      meaning or interpretation of any terms of provisions of this
      AGREEMENT.

            

    

    

    
      	
               
      

            	
              12.5.

            	
              No
      waiver of any provision of this AGREEMENT will be considered unless it is
      in a signed writing, and no such waiver will constitute a waiver of any
      other provision(s) or of the same provision on another
      occasion.

            

    

    
      
        
           

        

         

      

      
        Page 9 of
11

        
          

        

      

      
         

        
           

        

      

    

    

    
      	
              13.

            	
              INDEMNIFICATION

            

    

    

    
      	
               
      

            	
              13.1.

            	
              Indemnification
      by Macoven Pharmaceuticals .  Macoven
      Pharmaceuticals  shall defend, indemnify and hold Zyber, its
      affiliates, subsidiaries, successors, directors, officers, employees and
      agents harmless from and against any and all claims, suits, actions,
      damages, assessments, interest charges, penalties, costs or expenses,
      including reasonable attorney’s fees (collectively, the “Indemnified Amounts,”)
      arising out of (a) the material breach by Macoven Pharmaceuticals of any
      of its obligations, representations or warranties under this AGREEMENT,
      including, without limitation, Macoven Pharmaceuticals’ failure to submit
      payments to Zyber pursuant to Sections 7 and 8 of this AGREEMENT, (b) a
      negligent or willful act or omission on the part of Macoven
      Pharmaceuticals (including any employee or agent of Macoven
      Pharmaceuticals), (c) any federal or state claims or assessment for
      nonpayment or late payment by Macoven Pharmaceuticals of any tax or
      contribution based on compensation or other benefits owed to any employees
      of Macoven Pharmaceuticals, including, without limitation, a claim or
      assessment that Zyber should have withheld any amounts related thereto,
      (d) requests by Macoven Pharmaceuticals or by third parties (in connection
      with a claim against Macoven Pharmaceuticals ) pursuant to a subpoena or
      court order for the production by Zyber of documents or any other
      materials or to interview, depose and/or elicit testimony from Zyber
      employees on any matters related to or involving this AGREEMENT,
      including, but not limited to, the ADMINISTRATIVE SERVICES, (e) any
      violation by Macoven Pharmaceuticals of any and all APPLICABLE LAWS of any
      governmental body having jurisdiction over the exercise of rights under
      this AGREEMENT, or (f) any misuse or misappropriation of any products
      distributed by Macoven
Pharmaceuticals.

            

    

    

    
      	
              14.

            	
              INSURANCE

            

    

    

    
      	
               
      

            	
              14.1.

            	
              Macoven
      Pharmaceuticals Insurance Coverage Required.  During any term of
      this AGREEMENT, and with respect to liability hereunder for any post
      termination period during which a claim could be asserted against Macoven
      Pharmaceuticals, up to 5 years after termination, Macoven Pharmaceuticals
      shall maintain at its sole expense insurance coverage as
      follows:

            

    

    

    
      	
              14.1.1.

            	
              Product
      liability insurance with respect to any products developed as a result of
      this AGREEMENT with coverage limits of not less than $5 million per
      occurrence and $5 million in the aggregate;
and

            

    

    

    
      	
              14.1.2.

            	
              Commercial
      General Liability insurance including with a combined single limit of
      $1,000,000, minimum liability of $1,000,000 each occurrence and $2,000,000
      in the aggregate.

            

    

    

    
      	
              14.1.3.

            	
              The
      foregoing insurance shall be maintained with responsible carriers and
      their terms of coverage shall be evidenced by certificates of insurance to
      be furnished by Macoven Pharmaceuticals to Zyber within 30 days of the
      date of this AGREEMENT.  Such certificates of insurance shall
      provide that at least 30 days’ written notice shall be
    given

            

    

    
      
        
           

        

         

      

      
        Page 10
of 11

        
          

        

      

      
         

        
           

        

      

    

    
      	
               
      

            	
              to
      Zyber prior to cancellation or modification of any of the material terms
      of coverage of any policy.

            

    

    

    
      	
              15.

            	
              FORCE
      MAJEURE

            

    

    

    
      	
               
      

            	
              15.1.

            	
              Neither
      party shall be deemed to have breached this AGREEMENT or to be liable for
      any damages caused by failure to perform or by delay in rendering
      performance hereunder arising out of any occurrence or contingency beyond
      its reasonable control, including but not limited to, (a) flood,
      earthquake, hurricane, fire, war, strikes, labor unrest, riot, civil
      commotion, power or communication line failure, computer equipment failure
      or operational failure, (b) failure of independent contractors under
      agreement with Zyber to perform or (c) prohibition(s) or restriction(s)
      imposed by applicable regulatory authority, the judgment, ruling or order
      of a court or agency of competent jurisdiction, or the enactment of or
      change in any law or regulation.

            

    

    

    

    
      
        	
                 Zyber, Inc.

                 

                By:  Cooper Collins 

                 

              	 	 	
                 Macoven Pharmaceuticals,
      LLC.

                 

                By:  Mike Venters

              	 
	
                /s/
      Cooper Collins 

              	 	 	
                /s/ 
      Mike Venters

              	 
	
                Name:
      Cooper Collins  

              	 	 	
                Name:  Mike
      Venters

              	 
	
                Title:
      President 

              	 	 	
                Title:
      President

              	 
	 	 	 	 	 
	 Date:  July
      27, 2009	 	 	 Date:  July
      27, 2009	 

      

    

     

     

                                                                               

    

    

    

    
      
        
           

        

         

      

      
        Page 11
of 11ptx_ex103.htm

    
      EXHIBIT
10.3

    EMPLOYMENT
AND NON-COMPETE AGREEMENT

    

    

    THIS EMPLOYMENT AND NON-COMPETE
AGREEMENT (this “Agreement”) is
entered into and effective as of the 31st day of December, 2008 (the “Effective Date”), by
and between ZYBER
PHARMACEUTICALS, INC., a Louisiana corporation (“Employer”), and Michael Venters, a resident of
the lawful age of majority of the Commonwealth of Kentucky (“Employee”), who
hereby agree as follows:

    

    WHEREAS Employer desires to
employ Employee, and Employee desires to accept employment with Employer,
subject to the terms and conditions hereinafter set forth,

    

    NOW, THEREFORE, in
consideration of the premises and the mutual covenants hereinafter set forth and
for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, Employer and Employee, intending to be legally bound,
hereby agree as follows:

    

    1.   Period of
Employment.  Employer shall employ Employee, and Employee shall
serve Employer during the period commencing on the Effective Date, and
continuing through and including December 31, 2009 (the “Term”).  The
term of employment shall automatically renew each year.

    

    2.   Duties and
Responsibilities.  Employee shall be employed by Employer as
Vice President of Business Development.  As such, Employee shall
provide services typically provided by a VP of Business Development, including,
without limitation, Product Development, Co-Promotional Opportunities and other
related miscellaneous duties, and such other duties and responsibilities as may
from time to time be assigned to or vested in Employee by Employer’s Board of
Directors (the “Board”) or by any
officer of Employer superior to Employee.  Additionally, Employee’s
employment by Employer during the Term shall be subject to, and limited by, the
following conditions:

    

    (a)   Employee
shall be available to provide a minimum of forty-five (45) hours per week of
services to Employer.  Employee shall provide such services upon
request of Employer, but Employer shall not be obligated to request that such
services be provided.  So long as Employee is employed by Employer,
Employee shall devote Employee’s time, attention, skill and ability during
normal and usual business hours (and outside those hours when reasonably
necessary to fulfill Employee’s duties hereunder) to the faithful and diligent
performance of the duties and responsibilities described herein.

    

    (b)   Employee
shall (i) devote his full time, energy and attention during regular business
hours to the benefit and business of Employer in performing his duties pursuant
to this Agreement; (ii) not be employed by any other person on a full-time
basis; and (iii) not undertake any other activities (individually or
collectively), that conflict or materially interfere with the performance of
Employee’s duties hereunder.

    

    (c)   Employee’s
services shall be performed at Employer’s offices, as well as at such other
locations and subject to such travel requirements as reasonably necessary to the
performance of Employee’s duties hereunder.

    

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    3.   Compensation.  As
compensation for the Services to be rendered pursuant to this Agreement, during
the Term:

    

    (a)   Employer
shall pay to Employee an annual salary of Two-Hundred Thousand and No/100
($200,000) Dollars (the “Salary”), payable in
accordance with Employer’s normal salary payment schedule.  The
employer shall pay a bonus to employee based on performance of duties and the
conclusion of the first term of this contract that may range from 50% to 100% of
base salary.

    

    (b)   Employer
shall provide Employee with health insurance coverage paid by Employer, and
thereafter, the right to make COBRA insurance payments for health coverage by
Employer’s then insurance provider for the maximum period permissible by
law.

    

    (c)   As
additional consideration, Employer shall cause the Board to declare and issue a
dividend, which shall be non-taxable to Employee, on or before March 16, 2009,
to Employee, in an amount sufficient to pay all income tax liability which may
be owed by Employee resulting from his ownership of common stock of Employer for
the period from January 1, 2008 though the May 31, 2008 (the “Tax Amount”); provided,
however, that the parties agree that Employer may, for the purposes of
fulfilling its obligations under this Section 3(c),
pay the Tax Amount directly to the appropriate taxing authorities, and in such
case, Employer shall provide sufficient evidence of the same to Employee on or
before March 16, 2009.

    

    (d) Employer
shall reimburse Employee for all reasonable, ordinary, and necessary business
expenses incurred in the performance of Employee’s duties hereunder in
accordance with and subject to the terms and conditions of Employer’s then
prevailing expense policy, a copy of which has been provided to
Employee.  As a condition precedent to obtaining such reimbursement,
Employee shall provide to Employer any and all statements, bills or receipts
evidencing the expenses for which Employee seeks reimbursement, and such other
related information or materials as Employer may from time to time reasonably
require.

    

    4.   Termination.  Unless
Employee’s employment is terminated pursuant to this Section, Employer shall
continue to employ Employee and Employee shall continue to serve Employer
throughout the Term.

    

    (a)   This
Agreement shall terminate automatically upon Employee’s death.

    

    (b)   For
purposes of this Agreement, Employee shall be deemed to be under a disability if
Employee shall be unable, by virtue of illness or physical or mental incapacity
or disability (from any cause or causes whatsoever), to perform Employee’s
essential job functions hereunder, whether with or without reasonable
accommodation, in substantially the manner and to the extent required hereunder
prior to the commencement of such disability, for a period exceeding thirty (30)
days (a “Disability”).  In
light of the unique nature of Employee’s services, and the undue burden on
Employer that would result from Employee’s long term absence, Employer shall
have the right to terminate Employee’s employment hereunder in the event
Employee shall remain under a Disability for a period exceeding thirty (30)
days, such termination to occur at the end of any calendar month during the
continuance of such disability, upon at least thirty (30) days’ prior written
notice to Employee.

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    (c)   Additionally,
Employer shall have the right to terminate Employee’s employment for “Cause” at any time
and without prior notice and without payment of any severance allowance or
further compensation beyond the date of termination.  For purposes of
this Agreement, “Cause” shall include:
(i) material default or other material breach by Employee of Employee’s
obligations hereunder; (ii) failure by Employee to perform diligently and
competently Employee’s duties hereunder; or (iii) fraud, libel, slander,
dishonesty, or any other act by Employee that is detrimental to Employer or its
good will or damaging to its relationships with its customers, suppliers, or
employees, including, without limitation, (A) use of alcohol or illegal drugs
such as to interfere with the performance of Employee’s obligations hereunder,
(B) conviction of or, plea of guilty or no contest to a felony or any crime
involving moral turpitude, dishonesty, or theft; and (C) material failure by
Employee to comply with applicable laws or governmental regulations with respect
to Employer operations or the performance of Employee’s duties.

    

    (d)   Employer
may terminate Employee’s employment without Cause at any time and without prior
notice.  In the event of such termination, Employer shall pay to
Employee an amount equal to the balance of the then unpaid portion of the
Salary, net of all required and usual deductions.  After the first
term of the contract, if employee is terminated without cause, employer shall
pay to employee one year’s salary and provide health insurance for on year to
employee.

    

    (e)   In the
event of termination of this Agreement for any reason, the payments (if any)
required to be provided to Employee pursuant to this Section shall be in full
and complete satisfaction of any and all obligations owing to Employee pursuant
to this Agreement.

    

    5.   Confidential
Information.  Both during and after the Term, Employee shall
not, directly or indirectly, divulge, publish, communicate, or make available to
any person, corporation, governmental agency, or other entity (except in
performing Employee’s duties hereunder), or use for Employee’s own or any other
person or entity’s purposes or benefit, any trade secret, confidential business
information, or any other information, know how, designs, specifications,
techniques, methods, concepts, inventions, developments, discoveries,
improvements, knowledge, or data of Employer which is not generally known to the
public (separately and collectively, “Confidential
Information”) (including, but not limited to, Confidential Information
relating to research, product development or design, manufacturing or
manufacturing processes, maintenance or repair processes, purchasing, product or
material costs, sales or sales strategies or prospects, pricing or pricing
strategies, advertising or promotional programs, product information, or mailing
or customer lists, finances (including prices, costs, and revenues), and other
business arrangements, plans, procedures and strategies), and shall use
Employee’s best efforts to prevent the publication or disclosure by any other
person or entity of any such Confidential Information.  Employer shall
not be under any obligation to identify specifically by any notice or other
action any Confidential Information to which this Section shall
apply.  The confidentiality obligations of Employee hereunder shall
specifically apply to any such Confidential Information obtained by Employee
prior to the Effective Date as a result of (a) Employee’s former ownership of
the stock of Employer, (b) Employee’s employment with Employer prior to the
Effective Date, (c) Employee’s prior position as an officer and/or member of the
Board, or (d) any other source.  While Employee is employed by
Employer, all documents and Confidential Information compiled, received, held or
used by Employee in connection with the business of Employer shall remain
Employer’s property, and shall be delivered by Employee to Employer upon the
termination of Employee’s employment, for whatever reason, or at any earlier
time requested by Employer.

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    6.   Unfair
Competition.

    

    (a)   Employee
agrees and acknowledges that, by virtue of Employee’s employment and position
with Employer, Employee shall have access to and maintain an intimate knowledge
of Employer’s activities and affairs, including Confidential Information, trade
secrets, confidential business information, and other confidential
matters.  As a result of such access and knowledge, and because of the
special, unique, and extraordinary services that Employee is capable of
performing for Employer or one of its competitors, Employee acknowledges that
the Services to be rendered by Employee pursuant to this Agreement are of a
character giving them a peculiar value, the loss of which cannot adequately or
reasonably be compensated solely by money damages.  Consequently,
Employee agrees that any breach or threatened breach by Employee of Employee’s
obligations under this Section, or of Section 5 or
Section 7
of this Agreement, would cause irreparable injury to Employer, and that Employer
shall be entitled to (i) preliminary and permanent injunctions enjoining
Employee from violating such provisions, and (ii) money damages in the amount of
fees, compensation, benefits, profits or other remuneration earned by Employee
or any competitor as a result of any such breach, together with interest, and
costs and attorneys’ fees and paralegals’ fees expended to collect such damages
or secure such injunctions.  Nothing in this Agreement, however, shall
be construed to prohibit Employer from pursuing any other remedy, Employer and
Employee having agreed that all such remedies shall be cumulative.

     

    (b)   For
purposes of this Agreement, the term “Business of Employer”
shall mean the development, marketing, sale, and/or licensing of pharmaceutical
products and the related intellectual property rights with respect thereto
(“Products”).  The
term “Products”
shall include products similar in targeted effect and use to Employer’s current
line of adult strength liquids and tablets, pediatric medications, upper
respiratory medications, women’s health medications, nutritional products, pain
relief products and medications, antibiotics, gastroenterology products and
medications, and any other products developed, sold, marketed, licensed or used
by Employer during Employee’s employment by Employer.

    

    7.   Solicitation of
Employees.  As a condition of employment with Employer, and as
a further material inducement to Employer to employ Employee hereunder, Employee
agrees that, while Employee is employed by Employer, and for a period of two (2)
years thereafter, Employee shall not, directly, or indirectly (as an employee,
member shareholder, agent or contractor for another person or entity), solicit,
hire or induce the termination from employment with Employer of any person who
was employed by Employer, or induce such person to accept employment other than
with Employer.

    

    8.   Inventions.  Employee
hereby agrees that any and all improvements, inventions, discoveries,
developments, creations, formulae, processes, methods, or designs, and any
documents, things, or information relating thereto, whether patentable or not
(individually and collectively, “Work Product”) within
the scope of or pertinent to any field of business or research in which Employer
is engaged or (if such is known to or ascertainable by Employee) considering
engaging, which Employee may conceive or make, or may have conceived or made
during Employee’s employment with Employer or during Employee’s former ownership
of stock in Employer, whether alone or with others, at any time within or
without normal working hours, shall be and remain the sole and exclusive
property of Employer.  Employer shall have the full right to use,
assign, license or transfer all rights to or relating to Work
Product.  Employee shall, whenever requested to do so by Employer
(whether during Employee’s employment or thereafter), at Employer’s expense,
execute any and all applications, assignments, or other instruments, and do all
other things (including giving testimony in any legal proceeding) which Employer
may deem necessary or appropriate in order to (a) apply for, obtain, maintain,
enforce, or defend letters patent or copyright registrations of the United
States or any, other country for any Work Product, or (b) assign, transfer,
convey, or otherwise make available to Employer any right, title or interest
which Employee might otherwise have in any Work Product.  Employee
shall promptly communicate, disclose, and, upon request, report upon and deliver
all Work Product to Employer, and shall not use or permit any Work Product to be
used for any purpose other than on behalf of Employer, whether during Employee’s
employment or thereafter.

    

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

     
9.   Additional
Obligations.  Both during and after the Term, Employee shall,
upon reasonable notice, furnish Employer with such information as may be in
Employee’s possession, and cooperate with Employer, as may reasonably be
requested by Employer (and, after the Term, with due consideration for
Employee’s obligations with respect to any new employment or business activity)
in connection with any litigation in which Employer is or may become a
party.  Employer shall reimburse Employee for all reasonable expenses
incurred by Employee in fulfilling Employee’s obligations under this
Section.

    

    10.      
Policies and
Procedures.  Employer shall have the authority to establish
from time to time the policies and procedures to be followed by Employee in
handling the business of the Employer.

     

    11.      
Mediation.  With
respect to any disputes arising out of or related to this Agreement, the parties
will first submit any such matter to non-binding mediation to take place in the
Parish of Orleans, Louisiana.  The parties shall share equally all
initial costs of mediation.  If mediation is not successful, the
parties may thereafter bring any additional legal action or proceeding with
respect to this Agreement in the District Court for the Parish of Ascension,
State of Louisiana, in accordance with the terms and conditions of Section 12
below.

    

    12.      
Choice of Venue; Waiver of
Right to Jury Trial.  Except as provided in Section 11
hereof with respect to the venue for mediation, any legal action or proceeding
with respect to this Agreement shall be brought in the District Court for the
Parish of Ascension, State of Louisiana.  The parties hereto hereby
waive the right to a jury trial in any action, proceeding or counterclaim
arising out of, or related to, the terms, conditions or enforcement of this
Agreement, or any other aspect of the acts, transactions or occurrences
described herein, or the transactions contemplated by or related to this
Agreement.  The prevailing party (upon the issuance of a final,
non-appealable judgment or order) shall be required to be reimbursed by the
other party for its or his reasonable attorneys’ and paralegals’ fees, experts’
fees and costs and fees related to the dispute, including costs of mediation or
other legal proceeding, in addition to any other relief to which that party may
be entitled.

     

    13.      
Confidentiality.  The
terms and conditions of this Agreement shall be confidential.  Neither
Employer or Employee shall disclose, directly or indirectly, this Agreement or
any of its terms and conditions, or any documents provided by Employer to
Employee pursuant to this Agreement, to any other person or entity without the
express written consent of the other unless required by law, court order, formal
process of a governmental agency or to enforce the terms of this Agreement;
provided,
however, that the parties acknowledge and agree that only to the extent
necessary to purse legal claims, to effect the transactions contemplated by this
Agreement and any agreements or transactions contemplated herein, this Section
shall not preclude the parties from disclosing this Agreement and its terms to
the parties’ respective lawyers and accountants for the limited purposes set
forth herein.

    

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    14.      
Governing
Law.  This Agreement shall be construed in accordance with, and
governed by, the Laws of the State of Louisiana applicable to agreements to be
performed entirely in the State of Louisiana without regard to its conflicts of
law rules.

    

    15.        
  Headings.  The
subject headings of the sections of this Agreement are included for purposes of
convenience only, and shall not control or affect the meaning, construction or
interpretation of any of its provisions.

    

    16.   Notice.  Any
notice or other communication required or permitted under this Agreement by
either party hereto to the other shall be in writing, and shall be deemed
effective upon (a) personal delivery, if delivered by hand, (b) three days after
the date of deposit in the mails, postage prepaid, if mailed by certified or
registered mail, or (c) the next business day, if sent by a prepaid overnight
courier service, and in each case addressed as follows:

    

     

    
      	If to Employee,
      to:  	
               Michael
      Venters

            
	 	
               

               

            
	If to Employer,
      to:  	
              Zyber
      Pharmaceuticals, Inc.

              1838
      Fern St.

              New
      Orleans, Louisiana 70118

              Attn:  James
      E. Smith, Jr.

            
	 	
               

               

            
	With a copy
      to:   	
              Cooper
      Collins

              32126
      Edgewater Drive

              Magnolia,
      Texas 77354

            
	 	
               

               

            
	With a copy
      to: 	
              Elkins,
      P.L.C.

              201
      St. Charles Ave; Ste. 4400

              New
      Orleans, Louisiana 70170

              Attn:
      Jordan B. Monsour, Esq.

            

    

     

    Either
party may change the address or addresses to which notices are to be sent by
giving notice of such change of address in the manner provided by this
Section

    

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    17.   Binding Effect;
Successors.  This Agreement shall be binding upon and shall
inure to the benefit of Employer and its successors and assigns, and shall inure
to the benefit of and be binding upon Employee and his executors,
administrators, heirs and legal representatives.  Because Employee’s
Services hereunder are special, personal and unique in nature, Employee may not
transfer, sell or otherwise assign his rights, obligations or benefits under
this Agreement.  Nothing in this Agreement shall preclude Employer
from assigning, in full or part, this Agreement to any affiliate of Employer, or
preclude Employer from consolidating or merging into or with, or transferring
all or substantially all of its assets to, another entity which assumes this
Agreement and all obligations and undertakings of Employer hereunder; provided,
however, said assignment shall be in a writing reasonably satisfactory to
Employee and the assignee shall assume all obligations of Employer hereunder,
and provided
further, that Employer shall not be released from, and shall continue to
be liable with respect to, its obligations hereunder as fully as if such
assignment had not been made.

    

    18.   Waiver.  No
waiver of a default by either party of any term, covenant or condition hereof to
be performed or observed by the other party shall be construed as, or operate
as, a waiver of any subsequent default of the same or any other term, covenant
or condition hereof.  No provision of this Agreement can be waived
unless such waiver is expressed in writing and signed by all of the parties
hereto.

    

    19.   No
Conflict.  Employee represents and warrants that Employee is
not subject to any agreement, order, judgment or decree of any kind which would
prevent Employee from entering into this Agreement or performing fully
Employee’s obligations hereunder.

    

    20.   Construction.  The
language of this Agreement shall be construed as a whole, according to its fair
meaning and intent and not strictly for or against any party, regardless of who
drafted or was principally responsible for drafting the Agreement or any
specific term or condition hereof.  The parties to this Agreement have
had sufficient time to consult legal counsel and negotiate changes regarding the
terms hereof.  This Agreement shall be deemed to have been drafted by
both parties to this Agreement, and neither shall urge otherwise.

    

    

    21.   Severability.  The
provisions of this Agreement are severable.  The parties intend that
if any provision of this Agreement should be adjudged invalid or unenforceable
in any jurisdiction, then such provision shall, as to such jurisdiction only, be
ineffective to the extent of such invalidity or unenforceability without
invalidating the remaining provisions hereof, provided such invalidity does not
materially prejudice either party in its or his rights and obligations contained
in the valid provisions of this Agreement, and any such invalidity or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.

    

    22.   Counterparts; Entire
Agreement; Modification.  This Agreement may be executed in
multiple counterparts, all of which together shall constitute one and the same
instrument.  Signatures by facsimile shall be considered valid and
binding on the parties hereto.  This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and
supersedes all prior and contemporaneous oral or written agreements,
representations, and understandings of the parties.  No supplement,
modification or amendment to this Agreement shall be binding unless executed in
writing by all parties to this Agreement.

    

    [COUNTERPART
SIGNATURES ON THE FOLLOWING PAGES]

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    COUNTERPART
SIGNATURE PAGE TO

    EMPLOYMENT
AND NON-COMPETE AGREEMENT

    BY AND
BETWEEN

    ZYBER
PHARMACEUTICALS, INC.

    AND

    MICHAEL
VENTERS

    
 

    THUS DONE AND SIGNED, at New
Orleans, Louisiana, in the presence of me, Notary Public, and the undersigned
competent witnesses on the 31st day of DECEMBER, 2008, after a due reading of
the whole.

     

    
       

      
        
          	WITNESSES: 	
                  EMPLOYER:

                   

                	 
	 
      

                  Print
      Name: _____________________________________

                	ZYBER
      PHARMACEUTICALS, INC.	 
	 	 	
                   

                   

                	 
	
                   

                	
                  By:
      

                	/s/ Cooper
    Collins  	 
	 	Name: Cooper
      Collins	 
	Print
      Name:
      ______________________________________                              	Its:      
      President	 
	 	 	 	 

        
                                                                                   

    

     

    [COUNTERPART
SIGNATURES ON THE FOLLOWING PAGE]

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

    

    COUNTERPART
SIGNATURE PAGE TO

    EMPLOYMENT
AND NON-COMPETE AGREEMENT

    BY AND
BETWEEN

    ZYBER
PHARMACEUTICALS, INC.

    AND

    MICHAEL
VENTERS

    

    

    THUS DONE AND SIGNED, at New
Orleans, Louisiana, in the presence of me, Notary Public, and the undersigned
competent witnesses on the 31st day of DECEMBER, 2008, after a due reading of
the whole.

    
       

      
        
          	
                  WITNESSES:

                  ______________________________________________

                	
                  EMPLOYER:

                   

                	 
	Print
      Name: _____________________________________	ZYBER
      PHARMACEUTICALS, INC.	 
	 	 	
                   

                   

                	 
	
                   

                	
                  By:
      

                	/s/ Michael Venters  	 
	_______________________________________________ 	 	 MICHAEL VENTERS	 
	Print
      Name:
      ______________________________________                              	           
      	 

        
                                                                                   

       

      
        
           

        

        
          9

          
            

          

        

        
           

        

      

    

     

    EXHIBIT
A

    

    Non-Compete
Territories

     

    I.  LOUISIANA
PARISHES:

    

    Acadia
Parish, Allen Parish, Ascension Parish, Assumption Parish, Avoyelles Parish,
Beauregard Parish, Bienville Parish, Bossier Parish, Caddo Parish, Calcasieu
Parish, Caldwell Parish, Cameron Parish, Catahoula Parish, Claiborne Parish,
Concordia Parish, De Soto Parish, East Baton Rouge Parish, East Carroll Parish,
East Feliciana Parish, Evangeline Parish, Franklin Parish, Grant Parish, Iberia
Parish, Iberville Parish, Jackson Parish, Jefferson Davis Parish, Jefferson
Parish, La Salle Parish, Lafayette Parish, Lafourche Parish, Lincoln Parish,
Livingston Parish Madison Parish, Morehouse Parish, Natchitoches Parish, Orleans
Parish, Ouachita Parish, Plaquemines Parish, Pointe Coupee Parish, Rapides
Parish, Red River Parish, Richland Parish, Sabine Parish, St. Bernard Parish,
St. Charles Parish, St. Helena Parish, St. James Parish, St. John The Baptist
Parish, St. Landry Parish, St. Martin Parish, St. Mary Parish, St. Tammany
Parish, Tangipahoa Parish, Tensas Parish, Terrebonne Parish, Union Parish,
Vermilion Parish, Vernon Parish, Washington Parish, Webster Parish, West Baton
Rouge Parish, West Carroll Parish, West Feliciana Parish, and Winn
Parish.

    

    II.  ALABAMA
COUNTIES:

    

    Autauga
County, Baldwin County, Barbour County, Bibb County, Blount County, Bullock
County, Butler County, Calhoun County, Chambers County, Cherokee County, Chilton
County, Choctaw County, Clarke County, Clay County, Cleburne County, Coffee
County, Colbert County, Conecuh County, Coosa County, Covington County, Crenshaw
County, Cullman County Dale County, Dallas County, De Kalb County, Elmore Count,
Escambia County, Etowah County, Fayette County, Franklin County, Geneva County,
Greene County, Hale County, Henry County, Houston County, Jackson County,
Jefferson County, Lamar County, Lauderdale County, Lawrence County, Lee County,
Limestone County, Lowndes County, Macon County, Madison County, Marengo County,
Marion County, Marshall County, Mobile County, Monroe County, Montgomery County,
Morgan County, Perry County, Pickens County, Pike County, Randolph County,
Russell County, Shelby County, St. Clair County, Sumter County, Talladega
County, Tallapoosa County, Tuscaloosa County, Walker County, Washington County,
Wilcox County, and Winston County.

    

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    TEXAS
COUNTIES:

    

    Anderson
County, Andrews County, Angelina County, Aransas County, Archer County,
Armstrong County, Atascosa County, Austin County, Bailey County, Bandera County,
Bastrop County, Baylor County, Bee County, Bell County, Bexar County, Blanco
County, Borden County, Bosque County, Bowie County, Brazoria County, Brazos
County, Brewster County, Briscoe County, Brooks County, Brown County, Burleson
County, Burnet County, Caldwell County, Calhoun County, Callahan County, Cameron
County, Camp County, Carson County, Cass County, Castro County, Chambers County,
Cherokee County, Childress County, Clay County, Cochran County, Coke County,
Coleman County, Collin County, Collingsworth County, Colorado County, Comal
County, Comanche County, Concho County, Cooke County, Coryell County, Cottle
County, Crane County, Crockett County, Crosby County, Culberson County, Dallam
County, Dallas County, Dawson County, De Witt County, Deaf Smith County, Delta
County, Denton County, Dickens County, Dimmit County, Donley County, Duval
County, Eastland County, Ector County, Edwards County, El Paso County, Ellis
County, Erath County, Falls County, Fannin County, Fayette County, Fisher
County, Floyd County, Foard County, Fort Bend County, Franklin County, Freestone
County, Frio County, Gaines County, Galveston County, . Garza County, Gillespie
County, Glasscock County, Goliad County, Gonzales County, Gray County, Grayson
County, Gregg County, Grimes County, Guadalupe County, Hale County, Hall County,
Hamilton County, Hansford County, Hardeman County, Hardin County, Harris County,
Harrison County, Hartley County, Haskell County, Hays County, Hemphill County,
Henderson County, Hidalgo County, Hill County, Hockley County, Hood County,
Hopkins County, Houston County, Howard County, Hudspeth County, Hunt County,
Hutchinson County, Irion County, Jack County, Jackson County, Jasper County,
Jeff Davis County, Jefferson County, Jim Hogg County, Jim Wells County, Johnson
County, Jones County, Karnes County, Kaufman County, Kendall County, Kenedy
County, Kent County, Kerr County, Kimble County, King County, Kinney County,
Kleberg County, Knox County, La Salle County, Lamar County, Lamb County,
Lampasas County, Lavaca County, Lee County, Leon County, Liberty County,
Limestone County, Lipscomb County, Live Oak County, Llano County, Loving County,
Lubbock County, Lynn County, Madison County, Marion County, Martin County, Mason
County, Matagorda County, Maverick County, McCulloch County, McLennan County,
McMullen County, Medina County, Menard County, Midland County, Milam County,
Mills County, Mitchell County, Montague Montgomery County, Moore County, Morris
County, Motley County, Nacogdoches County, Navarro County, Newton County, Nolan
County, Nueces County, Ochiltree County, Oldham County, Orange County, Palo
Pinto County, Panola County, Parker County, Parmer County, Pecos County, Polk
County, Potter County, Presidio County, Rains County, Randall County, Reagan
County, Real County, Red River County, Reeves County, Refugio County, Roberts
County, Robertson County, Rockwall County, Runnels County, Rusk County, Sabine
County, San Augustine County, San Jacinto County, San Patricio County, San Saba
County, Schleicher County, Scurry County, Shackelford County, Shelby County,
Sherman County, Smith County, Somervell County, Starr County, Stephens County,
Sterling County, Stonewall County, Sutton County, Swisher County, Tarrant
County, Taylor County, Terrell County, Terry County, Throckmorton County, Titus
County, Tom Green County, Travis County, Trinity County, Tyler County, Upshur
County, Upton County, Uvalde County, Val Verde County, Van Zandt County,
Victoria County, Walker County, Waller County, Ward County, Washington County,
Webb County, Wharton County, Wheeler County, Wichita County, Wilbarger County,
Willacy County, Williamson County, Wilson County, Winkler County, Wise County,
Wood County, Yoakum County, Young County, Zapata County, and Zavala
County.

    

    
      
         

      

      
        11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]